Xencor’s lead drug fails a PhII test for lupus, shares slide
Shares of Xencor tumbled Friday as the biotech tried to explain — largely unsuccessfully — why the failure of its Phase II lupus drug study was really …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
